Mobilize San Diego to accelerate cures for cancer in our lifetime.
Curebound’s giving is organized around a local cancer-research model in San Diego, with the largest recent awards going to UC San Diego and other La Jolla-based research institutions. The foundation’s grantmaking centers on translational oncology work that is meant to move from research into patient care, including prevention, detection, immunotherapy, novel therapeutics, and childhood cancer. Recent awards show support for both university-based science and early-stage biotech, with grants to The Regents of University of California UC San Diego, the La Jolla Institute for Immunology, and Sanford Burnham Prebys among the highest amounts in the file. That mix points to a funder that backs research institutions alongside companies pursuing clinical translation. Curebound also uses program-specific funding channels such as Catalyst Grants, Equity Grants, Targeted Grants, Cure Prizes, and Discovery Grants, each tied to cancer research projects in San Diego. Its grantmaking includes work on cancer disparities and underserved communities, pediatric cancer research, and collaborative projects that aim for patient application within a few years.
Cancer detection and treatment innovation are central to Curebound’s portfolio. In 2025, the foundation gave $250,000 to Beken Bio Inc for cancer research across its five research pillars, which include prevention and diagnostic tools, novel approaches and new therapeutic platforms, and personalized immunotherapy. It also awarded $250,000 to Palm Therapeutics Inc and $250,000 to Resolute Science Inc for the same broader research platform. The file also shows support for pediatric cancer research and care: Rady’s Children Hospital San Diego received multiple awards across 2023, 2024, and 2025, including a $21,431 grant in 2025. Equity-focused work appears through Curebound’s Equity Grants program, which targets medically underrepresented and underserved communities through prevention, screening, and detection efforts.
Curebound’s typical award size clusters tightly around the low-to-mid six figures: p25 is $225,575, median is $228,708, and p75 is $534,159. The recent grants list also shows a small number of larger research awards, including a $4,721,574 grant in 2025 and a $3,340,462 grant in 2024. The foundation is a regular funder, not a DAF, and the grant list shows repeated support for the same organizations across multiple years, especially in La Jolla and San Diego. Its active programs are project-based and accept unsolicited applications, with awards for one-time seed funding, larger clinical-stage projects, and multi-year prizes.
$10.2M
$11.9M
$11M
$14.9M
Most grants fall between $226K and $534K, with a median of $229K.
25th Percentile
$226K
Median
$229K
75th Percentile
$534K
Anne Marbarger
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Curebound gives locally and all listed grants go to U.S. recipients. The grant file is concentrated in California, with La Jolla appearing repeatedly alongside San Diego and Encinitas. Recent recipients include The Regents of University of California UC San Diego in La Jolla, the La Jolla Institute for Immunology in La Jolla, and Beken Bio Inc in San Diego. The geographic pattern is tightly clustered around the San Diego research ecosystem rather than spread across multiple states or countries.
Curebound supports cancer prevention, detection, treatment, immunotherapy, pediatric cancer research, cancer equity, and translational research. Its active programs also include Catalyst Grants, Equity Grants, Targeted Grants, Cure Prizes, and Discovery Grants, each tied to research projects in San Diego.
Yes. The active programs listed for Curebound — including Catalyst Grants, Equity Grants, Targeted Grants, Cure Prizes, Discovery Grants, and the Curebound Grants umbrella program — all note that they accept unsolicited applications.
The typical award size is in the low-to-mid six figures. The grant distribution shows p25 at $225,575, median at $228,708, and p75 at $534,159.
The grantmaking is local and all listed recipients are in the United States. California is the main recipient state, and recent grants repeatedly go to San Diego, La Jolla, and Encinitas.
The file shows repeated support for several organizations over multiple years. Examples include the same San Diego and La Jolla institutions appearing in 2023, 2024, and 2025 grant records, which indicates recurring support rather than isolated one-time awards.
2026
Source: IRS Form 990-PF, fiscal year 2026.
Current and upcoming funding from Curebound that your nonprofit may be able to apply for.
Who can apply: The grant must be led by an independent investigator affiliated with Rady Children's Health and requires either interdisciplinary or inter-institutional collaboration. Postdoctoral researchers are not eligible.
Deadline: The 2026 Childhood Cancers RFA was announced for release in late spring 2026; no closing deadline is provided.
Who can apply: Equity Grants were awarded in 2024 and 2025; Curebound indicates the Equity RFA is intended to be released over the summer in conjunction with the Childhood Cancers Award. Applicants must meet Curebound research program requirements and typically collaborate with San Diego-based research institutions.
Deadline: Expected summer 2026 RFA release in conjunction with the Childhood Cancers Award.
Who can apply: The PI must hold an MD, PhD, or equivalent and be an independent researcher at a cancer research institute based in San Diego. Postdoctoral researchers are not eligible. Proposals must include an independent interdisciplinary partner investigator; inter-institutional collaboration is encouraged but not mandatory.
Deadline: The 2026 grant application process and call for LOIs opened February 27; no closing deadline is provided.
Who can apply: The PI must hold an MD, PhD, or equivalent and be an independent researcher at a cancer research institute based in San Diego. Postdoctoral researchers are not eligible. Projects require inter-institutional collaboration.
Deadline: The 2026 grant application process and call for LOIs opened February 27; no closing deadline is provided in the scraped content.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| THE REGENTS OF UNIVERSITY OF CALIFORNIA UC SAN DIEGO | LA JOLLA, CA | $5,743,423 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| SANFORD BURNHAM PREBYS | LA JOLLA, CA | $1,529,548 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | LA JOLLA, CA | $849,414 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| SCRIPPS RESEARCH | LA JOLLA, CA | $537,267 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| LA JOLLA INSTITUTE FOR IMMUNOLOGY | LA JOLLA, CA | $385,027 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION | SAN DIEGO, CA | $337,270 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| ILLUDENT INC | SAN DIEGO, CA | $250,000 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| RESOLUTE SCIENCE INC | SAN DIEGO, CA | $250,000 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| BEKEN BIO INC | SAN DIEGO, CA | $250,000 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| UNIVERSITY OF ARIZONA | TUCSON, AZ | $100,000 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| RADY CHILDREN'S HOSPITAL | SAN DIEGO, CA | $6,650 | 2026 | SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS. |
| THE REGENTS OF UNIVERSITY OF CALIFORNIA UC SAN DIEGO | LA JOLLA, CA | $4,721,574 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| LA JOLLA INSTITUTE FOR IMMUNOLOGY | LA JOLLA, CA | $532,374 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| SANFORD BURNHAM PREBYS | LA JOLLA, CA | $411,561 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| BEKEN BIO INC | SAN DIEGO, CA | $250,000 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| RESOLUTE SCIENCE INC | SAN DIEGO, CA | $250,000 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| PALM THERAPEUTICS INC | SAN DIEGO, CA | $250,000 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| SEREN BIO CORP | ENCINITAS, CA | $250,000 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | LA JOLLA, CA | $207,926 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| SCRIPPS RESEARCH | LA JOLLA, CA | $188,618 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| RADY CHILDREN'S HOSPITAL | SAN DIEGO, CA | $21,431 | 2025 | SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS. |
| The Regents of University of California | La Jolla, CA | $3,340,462 | 2024 | Support Cancer Research |
| UC San Diego Foundation | La Jolla, CA | $838,596 | 2024 | Support Cancer Research |
| La Jolla Institute for Immunology | La Jolla, CA | $603,832 | 2024 | Support Cancer Research |
| Sanford Burnham Presbys Medical Discovery Institute | La Jolla, CA | $228,708 | 2024 | Support Cancer Research |
| Salk Institute for Biological Studies | La Jolla, CA | $228,708 | 2024 | Support Cancer Research |
| Rady's Childrens Hospital San Diego | San Diego, CA | $228,708 | 2024 | Support Cancer Research |
| Rady's Children Hospital San Diego | San Diego, CA | $225,575 | 2024 | Support Cancer Research |
| Scripps Research | La Jolla, CA | $225,000 | 2024 | Support Cancer Research |
| Sanford Burnham Presbys Medical Center | La Jolla, CA | $10,000 | 2024 | Support Cancer Research |
| UCSD Foundation | La Jolla, CA | $1,347,134 | 2023 | Support Cancer Research |
| La Jolla Institute for Immunology | La Jolla, CA | $464,486 | 2023 | Support Cancer Research |
| Sanford Burnham Presbys Medical | La Jolla, CA | $400,000 | 2023 | Support Cancer Research |
| Salk Institute for Biological Studies | La Jolla, CA | $385,950 | 2023 | Support Cancer Research |
| Rady's Children Hospital San Diego | San Diego, CA | $225,575 | 2023 | Support Cancer Research |
| Scripps Resarch | La Jolla, CA | $175,000 | 2023 | Support Cancer Research |
THE REGENTS OF UNIVERSITY OF CALIFORNIA UC SAN DIEGO
$5,743,423SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
SANFORD BURNHAM PREBYS
$1,529,548SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
$849,414SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
ILLUDENT INC
$250,000SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
RESOLUTE SCIENCE INC
$250,000SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
BEKEN BIO INC
$250,000SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
UNIVERSITY OF ARIZONA
$100,000SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
SEE DETAIL IN PART IVCUREBOUND AWARDS GRANT FUNDING IN EARLY-DISCOVERY CANCER RESEARCH AND APPLIES SCIENTIFIC AND ENTREPRENEURIAL EXPERTISE TO HELP PROMISING RESEARCH TRANSLATE INTO MEANINGFUL NEAR-TERM CLINICAL IMPACT. FUNDING IS DIRECTED TOWARD FIVE TRADITIONALLY UNDER-RESOURCED RESEARCH PILLARS: CANCER DETECTION, NOVEL APPROACHES, TARGETS, AND THERAPEUTICS. PERSONALIZED IMMUNOTHERAPY, CANCER EQUITY, CHILDHOOD CANCERS.
THE REGENTS OF UNIVERSITY OF CALIFORNIA UC SAN DIEGO
$4,721,574SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
SANFORD BURNHAM PREBYS
$411,561SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
BEKEN BIO INC
$250,000SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
RESOLUTE SCIENCE INC
$250,000SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
PALM THERAPEUTICS INC
$250,000SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
SEREN BIO CORP
$250,000SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
$207,926SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
SEE DETAIL IN PART IVCANCER RESEARCH ACROSS FIVE RESEARCH PILLARS; INCLUDING PREVENTION AND DIAGNOSTIC TOOLS, NOVEL APPROACHES AND NEW THERAPEUTIC PLATFORMS, IMMUNOTHERAPIES AND PERSONALIZED VACCINES, CANCER EQUITIES, AND PEDIATRIC CANCERS.
The Regents of University of California
$3,340,462Support Cancer Research
Sanford Burnham Presbys Medical Discovery Institute
$228,708Support Cancer Research
Salk Institute for Biological Studies
$228,708Support Cancer Research
Sanford Burnham Presbys Medical Center
$10,000Support Cancer Research
Sanford Burnham Presbys Medical
$400,000Support Cancer Research
Salk Institute for Biological Studies
$385,950Support Cancer Research
